Neurology

New research reveals how high blood sugar from type 2 diabetes alters brain function, mimicking early Alzheimer symptoms and impacting memory.

The breakthrough designation is supported by clinical data from ongoing phase 1/2 trials.

Nipocalimab with standard of care helped patients with generalized myasthenia gravis (gMG) maintain improvements in daily living and quantitative scores compared with placebo.

The future holds the promise of earlier diagnosis, more targeted therapies, and personalized neurological care, said speaker William D. Freeman, MD, FAAN.

Huntington disease (HD) has no curative treatments, therefore, there is a great need for therapies that can reduce or slow the progression of symptoms.

Numerical differences were observed as early as Month 1.

Advanced practice provider (APP) care models allow for health systems to better individualize care for patients, effectively meeting their needs.

Nilufer Ertekin-Taner outlines how embracing the biological complexity of neurodegenerative diseases can guide the development of precision therapies akin to those used in oncology.

Current recommended levels of vitamin B12 might not be sufficient to protect against neurological decline.

As indicated by prior literature, a second dose of intravenous immunoglobulin (IVIG) in patients with Guillain-Barré syndrome increases serum immunoglobulin G levels without improving clinical outcomes.

By examining the evidence, pharmacists can gain insights into whether these supplements could be integrated into MS treatment regimens to improve patient outcomes.

Pharmacists are crucial in Elevidys administration, ensuring accurate dosing, coordinating treatment timing, and managing adverse effects to optimize patient outcomes.

Long-acting injectables offer a promising approach to schizophrenia treatment, but their effective use requires careful management and patient education.

Currently, EN001 is undergoing evaluation in a phase 1b trial.

Elevidys offers significantly higher dystrophin production than existing Duchenne muscular dystrophy treatments but requires intensive monitoring for adverse events.

Given the increasing age of patients with generalized myasthenia gravis, knowing which therapies are most effective for different subgroups is essential.

LAIs offer a variety of benefits, from improved medication adherence and relapse prevention to enhanced quality of life for individuals with schizophrenia.

Amlenetug could provide a treatment option for patients with multiple system atrophy, a progressive and rare condition that causes damage to the brain’s nerve cells.

Risdiplam is the only approved non-invasive disease-modifying SMA treatment.

Supplements, such as Prevagen, as well as lifestyle and diet modifications can provide additional support to patients with Alzheimer disease.

Compared with other treatments for myasthenia gravis, nipocalimab demonstrated more significant improvements in disability scores, with tolerable safety.

Pregnant individuals with multiple sclerosis (MS) are more likely to experience mental illness both during their pregnancy and in the first years after giving birth.

The approval marks the first subcutaneous infusion device approved for the treatment of Parkinson disease, providing a new option for patients with serious disease who are unresponsive to other therapies.

Health care professionals, particularly pharmacists, can recommend that patients take over-the-counter supplements, such as melatonin, to facilitate REM sleep.

Meloxicam and rizatriptan reduces migraine pain and help patients return to normal functioning with efficacy through 24 to 48 hours after a single dose for some patients.

Administered every 4 weeks, the approval could serve as a breakthrough for easier and more effective care for patients with early Alzheimer disease.

Pharmacists bridge communication gaps and enhance shared decision-making.

Memantine/donepezil and everolimus are used to treat dementia of the Alzheimer type and tuberous sclerosis complex-associated subependymal giant cell astrocytoma, respectively.

Patients with multiple sclerosis being treated with glatiramer acetate have an increased risk of experiencing anaphylaxis.

These drugs are set to revolutionize their respective disease states in 2025.